Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Johnson and Johnson
AstraZeneca
Medtronic
Merck

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,294,196

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,294,196 protect, and when does it expire?

Patent 6,294,196 protects BONIVA and is included in one NDA.

This patent has forty-three patent family members in thirty-one countries.

Summary for Patent: 6,294,196
Title: Pharmaceutical composition containing diphosphonic acid or salt thereof
Abstract:The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.
Inventor(s): Gabel; Rolf-Dieter (Schwetzingen, DE), Preis; Walter (Neustadt, DE), Woog; Heinrich (Laudenbach, DE)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:09/413,990
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,294,196
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 6,294,196

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-001 May 16, 2003 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-002 Mar 24, 2005 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,294,196

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98119102Oct 09, 1998

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
AstraZeneca
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.